A review on Parkinson’s disease treatment

Lee, Tori K.; Yankee, Eva L.

doi:10.20517/2347-8659.2020.58

Cited by 56 publications

(52 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Parkinson’s disease is a neurodegenerative disease for which no cure yet exists 39 . But treatments exist 40 , which can help alleviate and control the symptoms of the disease and maintain the quality of live.…”

Section: Discussionmentioning

confidence: 99%

Use of common spatial patterns for early detection of Parkinson’s disease

Smrdel

2022

Sci Rep

View full text Add to dashboard Cite

One of the most common diseases that affects human brain is Parkinson’s disease. Detection of Parkinson’s disease (PD) poses a serious challenge. Robust methods for feature extraction allowing separation between the electroencephalograms (EEG) of healthy subjects and PD patients are required. We used the EEG records of healthy subjects and PD patients which were subject to auditory tasks. We used the common spatial patterns (CSP) and Laplacian mask as methods to allow robust selection and extraction of features. We used the derived CSP whitening matrix to determine those channels that are the most promising in the terms of differentiating between EEGs of healthy controls and of PD patients. Using the selection of features calculated using the CSP we managed to obtain the classification accuracy of 85% when classifying EEG records belonging to groups of controls or PD patients. Using the features calculated using the Laplacian operator we obtained the classification accuracy of 90%. Diagnosing the PD in early stages using EEG is possible. The CSP proved to be a promising technique to detect informative channels and to separate between the groups. Use of the combination of features calculated using the Laplacian offers good separability between the two groups.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of common spatial patterns for early detection of Parkinson’s disease

Smrdel

2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Generally, sporadic PD is a progressive neurodegenerative disease, which is characterized by signs and symptoms of progressive motor and non-motor dysfunctions (e.g., sleep disturbance) [ 29 ]. The sporadic forms of PD are associated with various aggressive environmental factors, including the effects of neurotoxins (e.g., 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP; its derivative 1-methyl-4-phenylpyridinium, or MPP+, interferes with the complex I), pesticides and herbicides, such as rotenone and paraquat [ 30 , 31 , 32 ], as well as factors, such as aging, traumatic brain injury, vascular risk factors, hypertension, diabetes mellitus, obesity and metabolic syndrome, depression, drugs addiction, physical inactivity, smoking, and alcohol consumption [ 33 , 34 , 35 , 36 ]. Such impacts lead to the appearance of an excess of electrons, the formation of ROS, and oxidative stress.…”

Section: Familial and Sporadic Forms Of Pd Epigenetic Aspectsmentioning

confidence: 99%

“…Options for ablative surgery include pallidotomy (destruction of the globus pallidus), thalamotomy (destruction of the thalamus), and subthalamotomy (destruction of the subthalamic nucleus). Operations can be uni- or bilateral and are aimed at reducing excessive inhibition from the globus pallidus and SN [ 36 , 308 ]. The possibilities of drug therapy for PD are limited and are mainly aimed at increasing the level of DA through the introduction of the physiological precursor of dopamine 1-3,4-dihydroxyphenylalanine (L-DOPA or levodopa), which crosses the BBB and is metabolized into DA.…”

Section: Treatment and Optimization Of The Condition Of Patients With Pdmentioning

confidence: 99%

Molecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease

Dolgacheva

Зинченко

Гончаров

2022

IJMS

View full text Add to dashboard Cite

An increasing number of the population all around the world suffer from age-associated neurodegenerative diseases including Parkinson’s disease (PD). This disorder presents different signs of genetic, epigenetic and environmental origin, and molecular, cellular and intracellular dysfunction. At the molecular level, α-synuclein (αSyn) was identified as the principal molecule constituting the Lewy bodies (LB). The gut microbiota participates in the pathogenesis of PD and may contribute to the loss of dopaminergic neurons through mitochondrial dysfunction. The most important pathogenetic link is an imbalance of Ca2+ ions, which is associated with redox imbalance in the cells and increased generation of reactive oxygen species (ROS). In this review, genetic, epigenetic and environmental factors that cause these disorders and their cause-and-effect relationships are considered. As a constituent of environmental factors, the example of organophosphates (OPs) is also reviewed. The role of endothelial damage in the pathogenesis of PD is discussed, and a ‘triple hit hypothesis’ is proposed as a modification of Braak’s dual hit one. In the absence of effective therapies for neurodegenerative diseases, more and more evidence is emerging about the positive impact of nutritional structure and healthy lifestyle on the state of blood vessels and the risk of developing these diseases.

show abstract

“…[6] Given the importance of both motor and non-motor symptoms of PD, treatment for PD should include pharmaceutical interventions, along with rehabilitative and maintenance therapy, mental health services. [8] As part of a broader portfolio of research on how people living with PD access health care and information, this analysis uses Medicare program data to explore the demographic characteristics, including gender, age, race and ethnicity, and rural residency ("urbanicity"), and PD-related health care utilization of Medicare beneficiaries living with PD using comprehensive data on Medicare beneficiaries and services made available by the Centers for Medicare & Medicaid Services. The implications of this study are particularly important when considered along with recent growth rates of incident Parkinson's disease in the US population, which increased more than 50 percent over the past decade (2012-2020), as well as the increase in the American population and associated projected growth of the Medicare population, which is expected to grow by 20.3% between 2021 and 2029.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Health Care Utilization of US Medicare Beneficiaries Living with Parkinson’s Disease

Pearson¹,

Hartzman²,

Munevar³

et al. 2022

Preprint

View full text Add to dashboard Cite

The number of people living with Parkinson’s disease (PD) is expected to rise in the coming years. This study analyzed health care utilization patterns of Medicare beneficiaries with a PD diagnosis (ICD-10 code G20) who were enrolled in 2019. Utilization analysis included PD-related specialists and primary care physicians, therapy services, and mental health services. We found 685,116 (1.2%) Medicare beneficiaries had PD (56.3% male, 77.9% over age 70, 85.3% White, and 16.0% rural residents). Few Medicare beneficiaries with PD sought care from a movement disorder specialist (MDS) (9.1%); another 50.9% visited a general neurologist. Results reveal low utilization rates for therapy and even lower rates for mental health services. Overall healthcare utilization varied significantly by demographic group with women, people of color, and rural residents being less likely to access specialist care. Our findings emphasize the need for further research on population-specific barriers to accessing PD-related health care.

show abstract

A review on Parkinson’s disease treatment

Cited by 56 publications

References 109 publications

Use of common spatial patterns for early detection of Parkinson’s disease

Use of common spatial patterns for early detection of Parkinson’s disease

Molecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease

Health Care Utilization of US Medicare Beneficiaries Living with Parkinson’s Disease

Contact Info

Product

Resources

About